The Foundation supports research across basic, translational and clinical science to speed breakthroughs that can lead to the creation of new treatments and a better quality of life for people with Parkinson's disease.
Search or browse funded studies
Previously funded studies appear chronologically, with the most recent appearing first.
-
Research Grant, 2025Clinical Evaluation of 18F-FD4 as a Potential Alpha-synuclein PET Imaging Biomarker
-
Research Grant, 2025Applying the Neuronal Alpha-synuclein Disease Integrated Staging System in Multiple System Atrophy
Study Rationale: The neuropathological hallmark feature of Parkinson’s disease (PD) is the accumulation of a misfolded protein called alpha-synuclein in neurons, which qualifies PD as a neuronal...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Isoform Specific Suppression of dIRE-SNCA with an ASO
Study Rationale: Alpha-synuclein (SNCA) aggregation is a hallmark of Parkinson’s disease (PD). Rare SNCA genetic duplications and triplications cause early-onset PD, suggesting a link between SNCA...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Next Generation Treg Therapy for Parkinson’s Disease
Study Rationale: Parkinson’s disease (PD) occurs because of the degeneration of the neurons that produce the neurotransmitter dopamine. This causes the disease signs and symptoms. Nerve cell...
-
Parkinson’s Disease Therapeutics Pipeline Program, 2025Novel Small Molecules to Slow PD Progression in a Genetically Defined Subset of People with PD
Study Rationale: Currently, drug discovery efforts for neurodegeneration are almost exclusively focused on disease risk, not the progression biology that afflicts patients when they present with...
-
Research Grant, 2025Characterization of Research Antibodies for Parkinson’s Community-nominated Targets
Study Rationale: Antibodies are essential for detecting proteins, but nearly 50% of commercial antibodies fail to work reliably—like a GPS that’s only right half the time. In Parkinson’s research...
Apply for a Grant
Our funding programs support basic, translational and clinical research from academia and industry.